Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Chimerix Inc

CMRX
Current price
0.88 USD -0.056 USD (-5.91%)
Last closed 0.93 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 85 704 432 USD
Yield for 12 month -26.91 %
1Y
3Y
5Y
10Y
15Y
CMRX
21.11.2021 - 28.11.2021

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina. Address: 2505 Meridian Parkway, Durham, NC, United States, 27713

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

7 USD

P/E ratio

Dividend Yield

Current Year

+324 000 USD

Last Year

+33 824 000 USD

Current Quarter

+4 000 USD

Last Quarter

+11 000 USD

Current Year

+323 000 USD

Last Year

+33 377 000 USD

Current Quarter

+4 000 USD

Last Quarter

+11 000 USD

Key Figures CMRX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -92 974 000 USD
Operating Margin TTM -520250 %
PE Ratio
Return On Assets TTM -23.64 %
PEG Ratio
Return On Equity TTM -36.5 %
Wall Street Target Price 7 USD
Revenue TTM 324 000 USD
Book Value 2.17 USD
Revenue Per Share TTM 0.004 USD
Dividend Share
Quarterly Revenue Growth YOY -99.5 %
Dividend Yield
Gross Profit TTM -36 486 000 USD
Earnings Share -0.93 USD
Diluted Eps TTM -0.93 USD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics CMRX

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CMRX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation CMRX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 1.2136
Enterprise Value Revenue 3.5749
Price Sales TTM 264.5199
Enterprise Value EBITDA 1.0307
Price Book MRQ 0.444

Financials CMRX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CMRX

For 52 weeks

0.88 USD 1.57 USD
50 Day MA 1.07 USD
Shares Short Prior Month 1 261 761
200 Day MA 1.03 USD
Short Ratio 2.51
Shares Short 1 240 331
Short Percent 1.46 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

399.12 USD Microsoft Corporation -4.91 (-1.22%)
Detailed analytics

ETF funds


M

MDAXEX

207.85 CHF iShares MDAX UCITS ETF (DE) 0 (0%)
Detailed analytics

Metals


Gold

2175.88 USD Gold +5.94 (+0.27%)
Detailed analytics